Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip and Microfluidics 2020

Shannon Stott's Biography

Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School

The Stott laboratory is comprised of bioengineers and chemists focused on translating technological advances to relevant applications in clinical medicine. Specifically, we are interested in using microfluidics and imaging technologies to create tools that increase understanding of cancer biology and of the metastatic process. In collaboration with the Toner, Haber and Maheswaran laboratories, we have developed a microfluidic device that can isolate extraordinary rare circulating tumor cells (CTCs) from the blood of cancer patients. We are striving to employ new imaging modalities to extract as much information as possible from these rare cells while pushing the technology further for early cancer detection. Ultimately, we hope that by working in close partnership with the molecular and cell biologist at the Mass General Cancer Center, we can create new tools that directly impact patient care.

Shannon Stott Image

Tracking Tumor Extracellular Vesicles Using Microfluidics

Wednesday, 30 September 2020 at 10:00

Add to Calendar ▼2020-09-30 10:00:002020-09-30 11:00:00Europe/LondonTracking Tumor Extracellular Vesicles Using MicrofluidicsLab-on-a-Chip and Microfluidics 2020 in Virtual ConferenceVirtual

Advances in microfluidic technologies and molecular profiling have propelled the rapid growth and interest in achieving a ‘liquid biopsy’ in cancer. The ability to manipulate fluidics flows towards the goal of interrogating millions of particles per second provides a significant advantage over other technological approaches. Through a collaborative effort between bioengineers, biologists, and clinicians, my laboratory at Massachusetts General Hospital has developed microfluidic devices to isolate and characterize these EVs from whole blood. For this presentation, data will be presented on our effort to use our devices to serially track EVs in glioblastoma patients over time. Further, we will share details on some of our latest technologies in development. Through the microfluidic isolation of blood based biomarkers from patients, our goal is to obtain complementary data to the current standard of care to help better guide treatment and identify new biomarkers and putative therapeutic targets.

Add to Calendar ▼2020-09-28 00:00:002020-09-30 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics 2020Lab-on-a-Chip and Microfluidics 2020 in Virtual ConferenceVirtual